Donepezil, a representative drug used to treat AD, may potentially interact with drugs metabolized via CYP1A2-, CYP2D6-, and CYP3A4-related enzymes (75), and CYP1A2 is a major enzyme catalyzing the metabolism of caffeine. Here, CYP2D6 is linked to Alzheimer disease.